Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Drug development

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alois Alzheimer described the first patient with Alzheimer's disease (AD) in 1907 and today AD is the most frequently diagnosed of dementias. AD is a multi-factorial neurodegenerative disorder with familial, life style and comorbidity influences impacting a global population of more than 47 million with a projected escalation by 2050 to exceed 130 million. In the USA the AD demographic encompasses approximately six million individuals, expected to increase to surpass 13 million by 2050, and the antecedent phase of AD, recognized as mild cognitive impairment (MCI), involves nearly 12 million individuals.

What this study adds

Evidence grade: Low

This is a narrative review. This narrative review describes Alzheimer's disease as a multi-factorial disorder influenced by familial, lifestyle and comorbidity factors, with a global population projected to exceed 130 million by 2050. It provides background on the scale of the disease rather than reporting a new treatment, cure or prevention result.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kim, A. Y., Al Jerdi, S., MacDonald, R., & Triggle, C. R. (2024). Alzheimer's disease and its treatment-yesterday, today, and tomorrow. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2024.1399121

Vancouver

Kim AY, Al Jerdi S, MacDonald R, Triggle CR. Alzheimer's disease and its treatment-yesterday, today, and tomorrow. Frontiers in pharmacology. 2024. doi:10.3389/fphar.2024.1399121. PMID: 38868666.

BibTeX

@article{kim2024-38868666,
  author  = {Kim, A. Y. and Al Jerdi, S. and MacDonald, R. and Triggle, C. R.},
  title   = {{Alzheimer's disease and its treatment-yesterday, today, and tomorrow}},
  journal = {Frontiers in pharmacology},
  year    = {2024},
  doi     = {10.3389/fphar.2024.1399121},
  pmid    = {38868666},
  url     = {https://doi.org/10.3389/fphar.2024.1399121}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This narrative review describes Alzheimer's disease as a multi-factorial disorder influenced by familial, lifestyle and comorbidity factors, with a global population projected to exceed 130 million by 2050. It provides background on the scale of the disease rather than reporting a new treatment, cure or prevention result.

Study details

How this study scored 51/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 51 of 100.51 of 100 points earned49 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in pharmacology)
Journal's citation record 2 / 4 Frontiers in Pharmacology: journal h-index 242 (OpenAlex, 2026-10-29)
Study design 0 / 12 Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 83 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 20.8 citations a year over 4 year(s) since 2024
Impact for its field and year 4 / 6 Cited 19.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 3 other studies in this library
Still being cited 3 / 4 Cited 83 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Chris R. Triggle: h-index 56 (OpenAlex, whole career)
Institution's track record 1 / 3 Weill Cornell Medicine: institution h-index 1,163 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 38868666)
Free to read 2 / 2 Free to read
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 79.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Drug development from nearby years

Also in Drug development

124 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.

Similar studies

More on Drug development

See all studies in Drug development →